Chronic pain affects tens of millions of Americans and its inadequate treatment creates an enormous burden on our health care system, its patients and its clinicians. Gaining a better understanding of the basic mechanisms driving chronic pain has the potential to lead to therapeutics that can reverse chronic pain as opposed to currently available palliative treatments. Changes in gene expression in peripheral sensory neurons link initial injury to the development of chronic pain. Work in this area has focused on transcriptionally-mediated events. However, sensory neurons are large cells with peripheral terminals at great distances from the site of transcription, the nucleus. Hence, control of protein translation potentially affords these cells a mechanism to rapidly change gene expression in direct response to local signaling factors. We have demonstrated, through the previous period of grant support, that translation control indeed plays a vital role in changes in gene expression driving the transition to chronic pain. This discovery creates an important therapeutic opportunity because translation is controlled by a number of kinases (e.g. MNK1/2) which signal to proteins (e.g. eIF4E) involved in the rate-limited step of protein synthesis, translation initiation. We wil test the central hypothesis that translation control signaling is crucial for changes in nociceptor excitability after exposure to pain promoting compounds and for mediating phenotypic changes in nociceptors during the transition to chronic pain. Specifically we will examine a novel signaling pathway for pain plasticity: MNK1/2 kinase phosphorylation of eIF4E. Our hypotheses will be tested through 3 specific aims: 1) MNK1/2 signaling to eIF4E as a key signaling hub for behavioral plasticity leading to chronic pain, 2) MNK1/2 signaling to eIF4E as a critical step for plasticity in nociceptor excitability and 3) BDNF as a key translational target of MNK1/2 - eIF4E signaling in nociceptor phenotypic changes that promote chronic pain. The outcome of the completion of these aims will be an in-depth understanding of how translation regulation promotes nociceptive plasticity, the identification of a specific mechanism (eIF4E phosphorylation) and target (MNK1/2 kinase) as a potential pain therapeutic and novel regulatory mechanisms of BDNF translation and the role of this process in the transition to chronic pain.

Public Health Relevance

Pain is the most prominent reason that Americans seek medical attention and the lifetime population incidence of chronic pain in this country is 33%. This creates an enormous burden on medical care systems and society and leads to human suffering. The goal of our research is to further understand mechanisms driving chronic pain and develop therapeutic strategies to treat and potentially reverse pain based on these molecular insights.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-IFCN-B (03))
Program Officer
Oshinsky, Michael L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas-Dallas
Schools of Allied Health Profes
United States
Zip Code
Barragán-Iglesias, Paulino; Pineda-Farias, Jorge Baruch; Bravo-Hernández, Mariana et al. (2016) Predominant role of spinal P2Y1 receptors in the development of neuropathic pain in rats. Brain Res 1636:43-51
Burgos-Vega, Carolina C; Quigley, Lilyana D; Avona, Amanda et al. (2016) Dural stimulation in rats causes BDNF-dependent priming to subthreshold stimuli including a migraine trigger. Pain :
Pember, Stephen O; Mejia, Galo L; Price, Theodore J et al. (2016) Piperidinyl thiazole isoxazolines: A new series of highly potent, slowly reversible FAAH inhibitors with analgesic properties. Bioorg Med Chem Lett 26:2965-73
Mejia, Galo L; Asiedu, Marina N; Hitoshi, Yasumichi et al. (2016) The potent, indirect adenosine monophosphate- activated protein kinase activator R419 attenuates mitogen-activated protein kinase signaling, inhibits nociceptor excitability, and reduces pain hypersensitivity in mice. Pain Rep 1:
Davidson, Steve; Golden, Judith P; Copits, Bryan A et al. (2016) Group II mGluRs suppress hyperexcitability in mouse and human nociceptors. Pain 157:2081-8
Kim, Ji-Young V; Megat, Salim; Moy, Jamie K et al. (2016) Neuroligin 2 regulates spinal GABAergic plasticity in hyperalgesic priming, a model of the transition from acute to chronic pain. Pain 157:1314-24
Kim, Ji-Young V; Tillu, Dipti V; Quinn, Tammie L et al. (2015) Spinal dopaminergic projections control the transition to pathological pain plasticity via a D1/D5-mediated mechanism. J Neurosci 35:6307-17
Price, Theodore J; Inyang, Kufreobong E (2015) Commonalities between pain and memory mechanisms and their meaning for understanding chronic pain. Prog Mol Biol Transl Sci 131:409-34
Price, Theodore J; Prescott, Steven A (2015) Inhibitory regulation of the pain gate and how its failure causes pathological pain. Pain 156:789-92
Kandasamy, Ram; Price, Theodore J (2015) The pharmacology of nociceptor priming. Handb Exp Pharmacol 227:15-37

Showing the most recent 10 out of 48 publications